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Abstract
Plecanatide is a recently developed guanylate cyclase-C (GC-C) agonist and the
first uroguanylin analog designed to treat chronic idiopathic constipation (CIC)
and irritable bowel syndrome with constipation (IBS-C). GC-C receptors are
found across the length of the intestines and are thought to play a key role in
fluid regulation and electrolyte balance. Ligands of the GC-C receptor include
endogenous agonists, uroguanylin and guanylin, as well as diarrheagenic,
Escherichia coli heat-stable enterotoxins (ST). Plecanatide mimics uroguanylin
in its 2 disulfide-bond structure and in its ability to activate GC-Cs in a pH-
dependent manner, a feature associated with the presence of acid-sensing resi-
dues (Asp2 and Glu3). Linaclotide, a synthetic analog of STh (a 19 amino acid
member of ST family), contains the enterotoxin’s key structural elements,
including the presence of three disulfide bonds. Linaclotide, like STh, activates
GC-Cs in a pH-independent manner due to the absence of pH-sensing residues.
In this study, molecular dynamics simulations compared the stability of pleca-
natide and linaclotide to STh. Three-dimensional structures of plecanatide at
various protonation states (pH 2.0, 5.0, and 7.0) were simulated with GRO-
MACS software. Deviations from ideal binding conformations were quantified
using root mean square deviation values. Simulations of linaclotide revealed a
rigid conformer most similar to STh. Plecanatide simulations retained the flexi-
ble, pH-dependent structure of uroguanylin. The most active conformers of ple-
canatide were found at pH 5.0, which is the pH found in the proximal small
intestine. GC-C receptor activation in this region would stimulate intraluminal
fluid secretion, potentially relieving symptoms associated with CIC and IBS-C.
Abbreviations
CIC, chronic idiopathic constipation; FGID, functional gastrointestinal disorder;
GC-C, guanylate cyclase-C; GI tract, gastrointestinal tract; IBS-C, irritable bowel
syndrome with constipation; RMSD, root mean square deviation; ST, family of heat
stable enterotoxin produced by enterotoxigenic Escherichia coli that include STh
and STp; STh, 19 amino acid member of ST family.
Introduction
Chronic idiopathic constipation (CIC) and irritable bowel
syndrome with constipation (IBS-C) are two of the most
common conditions affecting the gastrointestinal (GI)
tract, creating a burden on healthcare resources and lead-
ing to significant negative impact on quality of life (Hei-
delbaugh et al. 2015). These disorders are characterized
by diminished stool frequency, straining and abdominal
pain (IBS-C) or discomfort (CIC). CIC alone affects 14%
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of the North American population, is challenging to treat
and poses a significant burden on health resources
(Suares and Ford 2011).
Guanylate cyclase-C (GC-C) receptors play a crucial
role in the maintenance of normal bowel function and
thus have potential as a target for pharmaceutical inter-
vention in to treat numerous functional gastrointestinal
disorders. The GC-C receptor is a membrane-spanning
protein uniformly expressed along the epithelial brush
border throughout the intestine (Forte 1999). Recently
plecanatide and linaclotide have been developed for the
treatment of two of these disorders, CIC and IBS-C
(Shailubhai et al. 2013).
The GC-C receptor is activated by its endogenous pep-
tides uroguanylin and guanylin that differentially bind to
the receptor in the varying pH environments found along
the GI tract (Fan et al. 1997). Uroguanylin is primarily
expressed and preferentially binds GC-C receptors in the
slightly acidic (pH 5-6) regions of the duodenum and
jejunum (Forte 1999). Guanylin is primarily expressed in
the ileum and colon, activating GC-C receptors under
more basic conditions (pH 7 -8) (Kita et al. 1994). Bind-
ing of uroguanylin or guanylin to the GC-C receptor ini-
tiates a signaling cascade leading to accumulation of
intracellular cyclic guanosine monophosphate (cGMP)
(Vaandrager et al. 1997), which helps maintain fluid and
electrolyte balance, promotes visceral analgesia, and
reduces inflammation in the GI tract (Hughes et al. 1978;
Pitari 2013; Shailubhai et al. 2015; Hanning et al. 2014).
The overlapping yet distinct activities of guanylin and
uroguanylin suggest that the tight and tunable regulation
of GC-C receptors is essential for proper GI function, a
feature that becomes readily apparent by the conse-
quences of dysfunctional GC-C activity (Whitaker et al.
1997). Overactivation of GC-C receptors by the E. coli
enterotoxin (STh) triggers an uncontrolled release of elec-
trolytes and water into the intestinal lumen resulting in
diarrhea (Brierley 2012).
Studies have shown STh to be 10 times more potent than
uroguanylin and 100 times more potent than guanylin in
binding to GC-C receptors (Hamra et al. 1993). The X-ray
structure of STh reveals that the molecule is locked into a
constitutively active, right-handed spiral formation stabi-
lized by three intrachain disulfide bridges in a 1-4/2-5/3-6
pattern (Gariepy et al. 1987; Ozaki et al. 1991; Shimonishi
et al. 1987). Unlike STh, the endogenous peptides have only
two disulfide bridges which likely results in their improved
flexibility; Klodt et al. (1997). The flexibility afforded by
absence of a third disulfide bridge allows uroguanylin and
guanylin to adopt two topological isoforms (A and B) of
which only the A form is biologically active (Marx et al.
1998; Skelton et al. 1994). The pH-dependent activity of
uroguanylin is linked to two charged acid-sensing aspartic
acid residues on its N-terminus (Hamra et al. 1997). The
absence of these residues within STh allows it to bypass pH
checkpoints governing GC-C receptor activation, allowing
for supraphysiological activation of GC-C along the length
of the small intestine and colon (Hamra et al. 1997).
Pharmacologic agonists that mimic the activity of
known GC-C agonists have been developed to treat
patients with CIC and IBS-C. Linaclotide, a synthetic ana-
log of STh, is available for the treatment of CIC and IBS-
C (Lembo et al. 2011). Like STh, linaclotide has three
disulfide bonds and demonstrates pH-independent activa-
tion of GC-C receptors (Fig. 1) (Busby et al. 2010).
Plecanatide is a recently developed GC-C agonist and
uroguanylin analog that is currently in Phase 3 trials for
CIC and IBS-C (Synergy Pharmaceuticals Inc 2015a,b).
Plecanatide is an orally administered, pH-dependent ago-
nist of the GC-C receptor that shares the structural and
physiological characteristics of uroguanylin. Plecanatide
has two disulfide bonds, similar to uroguanylin, and con-
tains two acidic N-terminal amino acids allowing the two
molecules to maintain the same pH-dependent binding
Figure 1. Amino acid structures of guanylate cyclase-C receptor
agonists examined in this study. Synthetic analogs linaclotide and
plecanatide share similar amino acid sequences with GC-C agonists
STh and uroguanylin, respectively. Plecanatide, like uroguanylin
contains two pH-sensing residues on its N-terminus. The pH-sensing
residue (aspartatic acid, D) of uroguanylin is replaced with another
pH-sensing residue (glutamic acid, E) in plecanatide (green). In this
study, the pH-sensing aspartic acid and glutamic acid residues of
plecanatide were differentially protonated to reflect pH values 2.0
(Asp2, Glu3), 5.0 (Asp2-,Glu3; Asp2, Glu3-) & ≥7.0 (Asp2-, Glu3-).
Simulations of the crystal structure of STh used a truncated version of
the full toxin, comprised of residues 5–17 of the full heat-stable
enterotoxin protein representing the core bioactive pharmacophore of
peptide. (A). STh and linaclotide both lack pH-sensing residues on
their N-terminal ends and are stabilized into a constitutively active
conformer by the presence of 3 disulfide bonds. Structurally, the
peptides differs by the replacement of leucine (L) in STh with tyrosine
(Y*) in linaclotide.
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characteristics (Fig. 1) (Shailubhai et al. 2013). Given the
experimental challenges of studying the unique character-
istics of its pH-sensitive structure, computational methods
were employed to characterize behavior of plecanatide at
various pH states.
Molecular dynamics (MD) simulations compared the
flexibility and conformation of plecanatide and linaclotide.
As expected, linaclotide was shown to adopt rigid confor-
mations, which do not deviate significantly from the struc-
ture of STh. In contrast, plecanatide showed greater
flexibility and an ability to adopt several conformations
which vary in response to pH values (2.0, 5.0 and 7.0).
Active plecanatide conformations were more similar to
uroguanylin than to the STh peptide, suggesting that pleca-
natide has a similar pH-dependent activity profile as uro-
guanylin and that plecanatide’s activity can be differentially
regulated in the GI tract, with higher activity in the more
acidic proximal small intestine and lower activity in the
more basic distal small intestine and colon.
Materials and Methods
Peptide preparation
The NMR structures of uroguanylin (PDB ID: 1UYA)
and the crystal structure of STa (PDB ID: 1ETN)
(Fig. S1) were used as starting points for the MD simula-
tions (Ozaki et al. 1991). The STa family of heat stable
peptides includes STh and STp (Nataro and Kaper 1998).
The series of experiments used in this study used the STh
sequence as reference.
Structural models of plecanatide, linaclotide, and STh
were built by appropriately modifying the uroguanylin and
STa sequences, respectively, using the builder tools in molec-
ular operating environment [(MOE 2015.4) www.chemc
omp.com]. (Molecular Operating Environment 2015).
Simulations and root mean standard deviation (RMSD)
values of linaclotide and each configuration of plecanatide
were compared to the enteric pathogen, STh, which was
selected as the reference peptide because of its enhanced
affinity for the GC-C receptor compared to other ago-
nists. The structural rigidity of STh confers one main
conformation that would bind the receptor. Similarities
to this one conformer would reflect a drugs ability to
activate GC-C.
MD simulations
All MD simulations of plecanatide, STh, and linaclotide
were performed and analyzed using the GROMACS 4.5
simulation package (Hess et al. 2008). MD simulations of
the structure of STh used residues 6–18 of the full heat-
stable enterotoxin protein (C-C-E-L-C-C-N-P-A-C-T-G-C),
considered to be the pharmacophore of the molecule
required for maximum biological activity (Ozaki et al.
1991; Yoshimura et al. 1985).
Four protonation states of plecanatide were modeled
by placing the appropriate charge on Asp2 and Glu3,
reflecting the most abundant species at three pH environ-
ments: pH 2.0 (Asp2, Glu3), pH 5.0 (Asp2-, Glu3; Asp2,
Glu3-), and pH 7.0 (Asp2-, Glu3-) (Fig. 1 circle). The ini-
tial structure of each peptide was placed in a cubic box
with TIP 3P water and energy minimized using a Steepest
Descent Minimization Algorithm. The system was equili-
brated via a 50 ps MD simulation at 310 K in a NVT
canonical environment followed by an additional 50 ps
simulation at constant pressure of 1 atm (NPT). After the
equilibration phases, a 500 ns MD simulations were per-
formed at constant temperature (310 K) and pressure
with a time step of 2 fs. The system energy and peptide
spatial coordinates (trajectory file) were stored every
300 ps for further studies. All MD simulations were run
in triplicate for each peptide.
After removing the first 100 ns, considered as system
stabilization time, the remaining 400 ns of the MD trajec-
tory of every single run for each group of triplicate exper-
iments were combined using the tricat function. The
combined trajectories (3999 frames) were examined using
the g-cluster function, setting gromos as the clustering
method with an RMSD cut-off of 0.1 nm. The different
structural cluster groups were obtained as a pdb file.
Cluster groups representing at least 10% of the total pop-
ulation for each peptide were selected as the most repre-
sentative structure for that peptide.
RMSD comparisons
The representative cluster conformations of the different
peptides were used for the RMSD comparison against the
main conformation of the STh cluster.
RMSD comparisons were performed using MOE 2015.4
with the major STh cluster structure serving as a reference
for the superimposition of other peptide conformations.
Results
MD clustering
Table 1 shows the results obtained from the structural
cluster calculations. From this data it is possible to appre-
ciate how flexible plecanatide is, compared to STh and
Linaclotide. The latter peptides generated more populated
cluster than any of the plecanatide forms. RMSD analysis
of each MD simulations calculated against the most rep-
resentative clusters also confirm this observation
(Fig. S1).
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MD simulations of STh and linaclotide
In addition to providing information on structure, the
simulations also provided information on the degree of
internal rigidity and flexibility within the peptide. This
can be observed in the MD simulations shown in Fig-
ure 2A, in which overlapping snapshots of STh show very
little deviation. The fact that the snapshots show a high
degree of overlap across all rounds of simulations indi-
cates that STh is a fairly rigid molecule with little internal
flexibility. This constrained geometry is thought to be
established by the three disulfide bonds of the peptide
leading to a structural rigidity and high binding affinity
of STh for the GC-C receptor (Ozaki et al. 1991).
MD simulations of linaclotide, which differs from the
STh peptide used in the simulations by one amino acid
substitution and an additional residue at the C-terminus,
also reveal a rigid molecule that adopts a similar confor-
mation as STh (Fig. 2B). The rigidity of this peptide was
also confirmed by a RSM fluctuation analysis of the MD
trajectory (Supplemental Information, Fig. S2). Some
variability can be seen within the C-termini of the pep-
tides, likely due to the extra amino acid in linaclotide
compared to STh. Moreover, the conformation of the
interaction loops (regions binding the GC-C receptor) is
homologous between the two molecules (Fig. 2B *)
(Ozaki et al. 1991).
MD simulations of plecanatide
MD simulations of plecanatide were conducted by alter-
ing the amino acid sequence of the NMR structure of
uroguanylin (Marx et al. 1998). Because pH has been
shown to alter the ability of uroguanylin to activate GC-C
receptors, simulations were conducted on the four ioniza-
tion states of plecanatide’s structure, reflecting three dif-
ferent pH values, by altering the protonation states of
Asp2 and Glu3 residues. It should be noted that pleca-
natide contains an additional pH-sensitive residue, Glu5.
However, unlike Glu3, its side chain is oriented away
from the interaction loop and, given its position between
the two disulfide bonds, Glu5 does not have the confor-
mational freedom to affect the orientation of the loop
itself. Furthermore, this specific residue is highly con-
served across the whole range of GC-C binding peptides,
and includes STh and linaclotide which are not affected
by pH variations (Busby et al. 2010). For these reasons,
the protonation state of Glu5 should not affect the activ-
ity of uroguanylin and plecanatide.
To represent plecanatide at pH 5.0, which corresponds
to the pH of the duodenum and proximal jejunum, two
Table 1. Representative cluster analysis.
Compound and
test condition
Cluster
size1
% On the
total frames2
Average
RMSD (A)  SD3
STh 2273 56 0.1252  0.0821
Linaclotide 3592 89 0.0715  0.0421
Plecanatide –
pH>7.0
1108 28 0.1827  0.0862
Plecanatide –
pH 5.0 (Asp-/Glu)4
524
497
446
13
12
11
0.3208  0.1325
0.2425  0.1044
0.1252  0.1107
Plecanatide –
pH 5.0 (Asp/Glu-)
610 15 0.2885  0.1363
Plecanatide – pH<2.0 709 18 0.2115  0.0825
1The cluster size refers to the number of frames that are forming the
cluster. The total number of frames is 3999.
2The % is calculated on the total number of frames.
3The average RMSD is calculated against the most representative clus-
ter conformation for each peptide.
4Three representative clusters were obtained for this peptide.
Figure 2. MD simulations of STh and linaclotide. (A) Overlapping snapshots of STh from MD simulations reveal that the peptide adopts a single
stable structure with little flexibility. (B) Superimposition of representative structures from the STh and linaclotide. Variations between structures at
the C-terminus reflects changes in conformation induced by the additional tyrosine of linaclotide. Simulations reveal that linaclotide adopts a
similar conformation as STh especially so within the region of the GC-C interaction loop. (*). MD, Molecular dynamics.
2017 | Vol. 5 | Iss. 2 | e00295
Page 4
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Computational Modeling of Plecanatide, a Uroguanylin Analog B. Andrea et al.
protonation configurations were analyzed. In one, Asp2 is
protonated (Asp/Glu-), whereas in the other, Glu3 is pro-
tonated (Asp-/Glu). These ionization states were based on
the consideration that, as these residues are on the flexible
N-terminus and exposed to solvent, their pKa values
would be between 3.5 and 4.5 (values dependent on the
input peptide conformation as calculated on http://bio
physics.cs.vt.edu/H++, version 3.2) (Anandakrishnan et al.
2012); hence, the monoprotonated states would likely be
present at pH 5.0. Simulations of the two protonation
states indicate that plecanatide is flexible at this pH and
can adopt several conformations. Figures 3A–C show an
overlay of the three predominant Asp-/Glu conformations
of plecanatide and STh, and Figure 3D shows the pre-
dominant Asp/Glu- conformation of plecanatide and STh.
In two of these structures (Fig. 3A and D), the interaction
loop (*) of plecanatide overlays well with that of STh,
indicating that these two conformations of plecanatide
are capable of binding to and subsequently activating GC-
C receptors.
Simulations of the double protonated form of pleca-
natide (Asp/Glu) were conducted to assess the structure
and dynamics of the peptide at pH 2.0. The plecanatide
conformations observed at this pH differ from those of
STh (Fig. 3E). Based on these results, plecanatide is unli-
kely to adopt a conformation capable of binding to GC-C
at this highly acidic pH level, a feature which would
mimic uroguanylin’s inability to activate GC-C receptors
at this pH.
Simulations of the double negative form of plecanatide
(Asp-/Glu-), which represent the protonation state
observed at pH > 7.0, reveal a single predominant pleca-
natide structure (Fig. 3F). The portion of the peptide that
interacts with the GC-C receptor adopts a different con-
formation in plecanatide than in STh indicating dimin-
ished activity of the molecule at this pH value.
Interestingly, in the Asp/Glu- ionization state of pleca-
natide at pH 5, an interaction occurred between the
negatively charged acidic side chain of Glu3 residue in
the N-terminus and the positively charged side chain of
Asn9 in the interaction loop (Fig. 4). This interaction
between the Glu3 residue of the N-terminus and the Asn9
residue of the interaction loop seems to stabilize pleca-
natide in its most active conformation at pH 5. This
Figure 3. Overlapping snapshots of STh and plecanatide at pH values 5.0 (A–D), 2.0 (E) and >7.0 (F) using MD simulations. (A–C) Overlay of the
three predominant Asp-/Glu conformations of plecanatide and STh at pH 5.0 (RMSD values – A: 2.38 A; B:2.48 A; C:3.44 A). (D) The
predominant Asp/Glu- conformation of plecanatide and STh at pH 5.0 (RMSD value–1.93 A). The overlapping conformation of the interaction
loops (*) in A and D suggest these are active forms of plecanatide able to bind to and stimulate GC-C receptors. (E) Plecanatide conformations at
pH 2.0 Asp/Glu differ from those of STh with no overlap of interaction loop (RMSD value–3.45 A). (F) Simulations of the double negative form of
plecanatide, Asp-/Glu-, representing the protonation state at pH > 7.0, reveal a single plecanatide structure that has a minimal overlap of the
interaction loop (RMSD value – 2.54 A). MD, Molecular dynamics.
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interaction was not observed at other pH values nor is it
expected to occur with uroguanylin as the Asp3 amino
acid in uroguanylin would not be of sufficient length to
interact with the Asn9 residue in its interaction loop.
Overall, the highly flexible behavior of plecanatide is
very similar to the one observed with the parent peptide
uroguanylin (Fig. 5). Indeed, the NMR structures avail-
able for the latter peptide show a high degree of confor-
mational variability that closely mimics plecanatide. The
RMS Fluctuation analysis on Plecanatide also confirms
this flexibility (Fig. S2). The interaction loop of the two
peptides overlaps generally very well. Some variability is
observed in the N-terminus, where the substitution of
Asp3 for Glu3 is present.
In summary, if we consider all simulation sets at pH
2.0, 5.0, and 7.0, we can observe that plecanatide has the
required flexibility at these pH values to switch between
numerous conformations. The most active forms of pleca-
natide were found with the two ionization states represen-
tative of pH 5.0 as revealed by the similarity of their
interaction loops with the corresponding regions in uro-
guanylin at pH 5 (Fig. 5) and STh (Fig. 3A and F). These
results are consistent with previous studies reporting that
plecanatide was designed to be more active at slightly
acidic pH values, mimicking the pH-sensitive behavior of
uroguanylin (Shailubhai et al. 2013).
Comparison of MD simulations
RMSD comparisons of the different peptides analyzed
were used to quantify the similarities between the struc-
tures. The STh structure was used as a reference and the
conformations of the different peptides were superim-
posed on the STh molecule to evaluate their similarity to
the prototype of the active peptide, with lower RMSD
values indicating more similarity. Table 2 shows the
RMSD value for each peptide, considering all the repre-
sentative clusters. With an RMSD of 1.28 A, the structure
of linaclotide is more similar to STh than to uroguanylin
or to any of the plecanatide variants. The RMSD values
of the different plecanatide conformations show how flex-
ible the peptide is. Interestingly, plecanatide presents
some conformations that are very close to the reference
STh (RMSD <2 A), suggesting a peak activity for pleca-
natide at this pH. Additionally, RMSD calculations reveal
Figure 4. Structure of plecanatide at pH 5.0, in the Asp/Glu-
ionization state. Interaction (*) between the negative charge of Glu3
residue on the pH-sensitive N-terminus and Asn9 residue in the
interaction loop potentially serves to stabilize this active conformation
of plecanatide.
Figure 5. Overlay of the most active conformation of plecanatide,
Asp/Glu-, (pH 5.0), with the active “A” NMR structure of uroguanylin.
The interaction loop of the two peptides overlaps generally very well
(*). Some variability is observed in the N-terminus, where the
substitution Asp3/Glu3 is present.
Table 2. RMSD comparison between STh and the most representa-
tive clusters of the different peptides simulated.
Compound and Test Condition RMSD–A
Linaclotide 1.28
Uroguanylin 1.2–2.341
Plecanatide - pH>7.0 2.54
Plecanatide – pH 5.0 (Asp-/Glu) 3.44, 2.48, 2.382
Plecanatide – pH 5.0 (Asp/Glu-) 1.93
Plecanatide – pH<2.0 3.45
1Range of RMSD values between STh and the 10 NMR conformations
of uroguanylin.
2Three representative clusters (>10% – see methods section) were
obtained for this peptide. RMSD comparisons of the different peptides
analyzed were used to quantify the similarities between the struc-
tures. Lower values indicate higher structural similarity with STh refer-
ence molecule.
2017 | Vol. 5 | Iss. 2 | e00295
Page 6
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Computational Modeling of Plecanatide, a Uroguanylin Analog B. Andrea et al.
that these four variants of plecanatide are the closest
structurally to the active A-form of uroguanylin. This is
consistent with the data described above, in which the
negative charge of Glu3 interacts with Asn9 in the inter-
action loop, potentially promoting an active conformation
of plecanatide. These results indicate that, in a manner
similar to uroguanylin, the activity of plecanatide is not
“all or nothing” but tunable based upon the pH of the
environment.
Discussion
Transmembrane GC-C receptors play a critical role in the
regulation of fluid and electrolyte homeostasis within the
GI tract (Brierley 2012; Steinbrecher 2014). This balance
is normally maintained by the pH-dependent activation
of these receptors by the endogenous ligands, uroguany-
lin, and guanylin (Forte 2004). Studies have shown that
these pH environments are maintained at differential val-
ues across the length of the gastrointestinal tract (Daniel
et al. 1985; Whitaker et al. 1997). In the slightly acidic
mucosal environments of the duodenum and proximal
jejunum (pH 5.0-6.0), uroguanylin is 10 times more
potent than in the slightly basic (pH 7.0-8.0) environ-
ments of the ileum and colon (Hamra et al. 1997). In
contrast, guanylin is significantly more potent at binding
GC-C receptors in the ileum and colon (pH 7.0-8.0) than
in the duodenum and proximal jejunum (pH 5.0-6.0),
where it is essentially inactive (Hamra et al. 1997). Struc-
tural shifts induced by pH environments alter the potency
of these ligands, allowing them to cooperatively regulate
GC-C receptor activation (Hamra et al. 1997). Any per-
turbation in the pH-dependent control of GC-C activa-
tion would disrupt the delicate balance of electrolytes and
fluids within the intestines. This disruption could be asso-
ciated with disorders such as obstruction, secretory diar-
rhea and inflammatory bowel disease (Field 2003;
Fiskerstrand et al. 2012).
Based on their physiology, GC-C receptors are a
promising therapeutic target in the treatment of numer-
ous gastrointestinal disorders such as CIC and IBS-C.
Both are common complaints among all age groups and
are associated with a substantial burden on healthcare
resources in the US (Drossman et al. 2009). While the
exact pathologic mechanism of these diseases remains an
area of intense study, the symptoms (i.e. diminished stool
frequency, hard/lumpy stools, straining abdominal symp-
toms) indicate an imbalance in fluid and electrolyte
homeostasis in the GI tract (Steinbrecher 2014).
As an analog of the pathological GC-C agonist STh,
linaclotide maintains many structural features of STh,
including the presence of three disulfide bonds and an
insensitivity to pH. MD simulations in this study show
that the addition of a third intramolecular bond makes
both STh and linaclotide insensitive to MD perturbations
(Ozaki et al. 1991). The structural similarity of these two
molecules is reflected by the low RMSD values of 1.28 A
for linaclotide. The amino acid substitutions that differen-
tiate linaclotide from STh further enhance the pharma-
cokinetic stability and proteolytic resistance of linaclotide,
allowing it to remain active across a longer portion of the
small intestine (Bharucha and Waldman 2010; Harris and
Crowell 2007). The absence of pH-sensing amino acid
residues would additionally give these molecules maxi-
mum biological activity across the range of pH environ-
ments in the GI tract. This lack of focused areas of
activity may induce excessive fluid secretion and explain
the increased incidence of diarrhea associated with lina-
clotide (Busby and Ortiz 2014; Carpick and Gariepy 1993;
Lembo et al. 2011).
Plecanatide, a GC-C agonist under investigation for
IBS-C and CIC, differs from linaclotide in its amino acid
sequence and number of disulfide bonds. Plecanatide
maintains many of the structural and functional charac-
teristics of endogenous ligand uroguanylin, including the
two disulfide bonds and the two N-terminal pH-sensing
acidic residues, which result in a molecule that can exhi-
bit differential levels of activity based upon the pH of the
environment. As a result, plecanatide has a more targeted
zone of activation, stimulating GC-C receptors under
acidic conditions in a way that is similar to uroguanylin
(Shailubhai et al. 2015).
MD simulations of plecanatide in this study revealed
plecanatide to be a flexible structure that is unlike STh or
linaclotide and one that is able to adopt numerous con-
formations in response to a range of simulated pH envi-
ronments. Optimally active conformations were observed
in pH 5.0 simulations which approximates the pH values
of the duodenum and proximal jejunum. This pattern of
optimal activity is similar to that of uroguanylin, indicat-
ing that plecanatide and uroguanylin are similar in both
structure and function (Shailubhai et al. 2013). In con-
trast, at simulated pH values of 2.0 and 7.0, plecanatide
adopted conformations that would make it less likely to
bind GC-C receptors. Across the range of assessed pH
values, MD simulations and RMSD analysis reveal that
the structure of plecanatide and the NMR structure of
uroguanylin are similar to each other (Fig. 5), and quite
dissimilar to the STh structure (1.93–3.45 A and 1.20–
2.34 A vs. STh, respectively).
As mentioned previously, the sole difference between
the structures of uroguanylin and plecanatide is the
replacement of an aspartic acid residue (Asp3) with a glu-
tamic acid residue (Glu3) in plecanatide (Fig. 1). Previous
studies have shown that while plecanatide has a similar
pH-dependent affinity for the GC-C receptor, it binds
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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with superior potency than uroguanylin (Shailubhai et al.
2000, 2015). Computational models in this study revealed
that at pH 5.0, the charged end of the Glu3 residue inter-
acts with the Asn9 residue, potentially serving to stabilize
the structure when it forms its most active conformation.
Interestingly, the corresponding interaction between Asp3
and Asn9 is not present in uroguanylin, probably because
the side chain of Asp3 is not long enough to reach Asn9.
Stabilizing the molecule in this way allows plecanatide to
remain in its active conformer for a longer period of time
at this pH and explain the superior binding profile of ple-
canatide versus uroguanylin witnessed in earlier studies.
Recognizing the acidic-to-basic pH gradient nature of the
GI tract, the simulations in this study suggest that, similar
to uroguanylin, plecanatide would be optimally active in
the more acidic environment that is present in the proximal
small intestine of the GI tract. The ability of plecanatide to
activate GC-C receptors in a targeted manner similar to the
endogenous ligand uroguanylin may help normalize bowel
movements and explain the low levels of adverse events
seen with the drug in early clinical trials (Shailubhai et al.
2013). Understanding the structural mechanisms by which
plecanatide and linaclotide activate GC-C receptors and
respond to pH could shed light on clinical differences
between the two therapeutic options.
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Figure S1. The graphs represent the RMSD variation dur-
ing the simulation for each peptide. The RMSD is calcu-
lated taking as reference the structure of the most
representative cluster for each peptide. In the case of Ple-
canatide-pH>5.0 (Asn-/Glu), three major clusters were
present. All the frames included in the interval between 0
and 0.1 A are part of the representative clusters for each
peptide.
Figure S2. Residues RMS fluctuation. It is clear how the
fluctuation is minimal for STh and Linaclotide due to the
higher rigidity of the two peptide. On the contrary, a
higher flexibility is obtained for the four Plecanatide pep-
tides, according to the different protonation states.
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